Julie M Collins, MD, MPH, is a fellowship-trained, board-certified medical oncologist. She specializes in diagnosing and treating all types of breast cancer (hormone receptor-positive, triple-negative, and HER2-positive) and carcinoma in situ of the breast. She offers patients advanced and highly specialized care, including chemotherapy, chemoimmunotherapy, targeted therapies, immunotherapy, endocrine therapies, and clinical trials. Dr. Collins has experience with phase I, II, and III clinical trials. Dr. Collins’ research focuses on the development of novel therapies for patients with breast cancer, specifically immunotherapies and therapies to overcome endocrine resistance.

Dr. Collins’ Philosophy of Care:

"I approach each patient from a humanistic perspective, considering not only their diagnosis but also who they are as a person. I seek to understand each patient’s goals and hopes while incorporating both standard therapies and novel approaches with an evidence-based mindset."

Conditions treated:

• All types of breast cancer (hormone receptor-positive, triple-negative, and HER2-positive)
• Early-stage breast cancer
• Metastatic breast cancer
• Carcinoma in situ of the breast 

Procedures performed:

• Chemotherapy
• Chemoimmunotherapy
• Targeted therapies
• Immunotherapy
• Endocrine therapies
• Clinical trials 

Area(s) of expertise:

• Breast cancer (hormone receptor-positive, triple-negative, and HER2/neu-positive)
• Carcinoma in situ of the breast
• Clinical trials

Research interests:

• Endocrine resistance-immunotherapies
• Clinical trials
• New drug development